Press release from Sanofi issued 18th November 2013 regarding the decision to halt all clinical trials and development of investigational JAK2 Agent Fedratinib (SAR302503)
Sanofi (EURONEXT: SAN and NYSE: SY) have announced their decision to halt all clinical trials and cancel plans for regulatory filings for the investigational JAK2 inhibitor fedratinib (SAR302503). This is following a risk-benefit analysis following recent reports of cases consistent with *Wernicke’s encephalopathy in patients participating in fedratinib clinical trials.
The press release is available here mpdvoice.org.uk/wp-content/...
Fedratinib is a novel, investigational JAK2 inhibitor that was under development for the treatment of the three main types of MPNs (myeloproliferative neoplasms): primary myelofibrosis (including those patients previously treated with Ruxolitinib) polycythaemia vera and essential thrombocythaemia.
If you are currently in a fedratinib trial you should have been contacted by your haematologist/physician who will determine the best alternative therapies available to you.
If you have any concerns regarding fedratinib please contact your haematologist.
*Wernicke’s encephalopathy – mental confusion or delirium occurring in combination with paralysis of the eye muscles, nystagmus and an unsteady gait.